Severe Euglycemic diabetic ketoacidosis with mixed Acid-Base disorder following acetazolamide initiation in type 2 diabetes: a case report and review of literature
Abstract
Euglycemic diabetic ketoacidosis (euDKA) is an increasingly recognized complication of sodium-glucose cotransporter-2 (SGLT2) inhibitor therapy, characterized by severe metabolic acidosis with near-normal blood glucose levels. We report a rare case of a 45-year-old woman with type 2 diabetes mellitus who presented with severe euDKA (pH 6.85, glucose 170 mg/dl) following initiation of acetazolamide for glaucoma management. Clinical evaluation revealed profound metabolic acidosis with bicarbonate 1.5 mmol/l and anion gap 27 mmol/l. Delta ratio calculation (0.64) revealed a mixed high anion gap and normal anion gap metabolic acidosis, indicating dual pathophysiology: ketoacid accumulation from euDKA and acetazolamide-induced renal bicarbonate wasting. Immediate acetazolamide discontinuation combined with aggressive fluid resuscitation, insulin infusion, and sodium bicarbonate resulted in complete metabolic correction by Day 3 without hemodialysis. To our knowledge, this rare combination of SGLT2 inhibitor use and acetazolamide underscores the need for careful medication reconciliation and multidisciplinary communication in diabetic patients to prevent complications.
How strong is the evidence?
Evidence Hub reads this as a case report, done in people. Its evidence level is 5 of 5 (Very low · case / narrative / animal / in vitro / in silico). Case reports, narrative reviews, and animal, cell or computer-model studies give the weakest evidence for human health.
Read the paper
Related studies
- Strategy for Mitigating DKA Risk in Patients with Type 1 Diabetes on Adjunctive Treatment with SGLT Inhibitors: A STICH Protocol
- Glucoraphanin: a broccoli sprout extract that ameliorates obesity-induced inflammation and insulin resistance
- SGLT2 Inhibitors in Heart Failure: Targeted Metabolomics and Energetic Metabolism
- Mechanisms of blood pressure reduction with sodium-glucose co-transporter 2 (SGLT2) inhibitors
- Sodium-glucose cotransporter inhibitors: beyond glycaemic control
- Decoding the effects of SGLT2 inhibitors on cardiac arrhythmias in heart failure
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.